HONG KONG, September 15 — Insilico Medicine is taking its AI drug-discovery engine into preventive medicine. The Hong Kong-listed company (HKEX: 3696) announced Longevity Vaccines, a research initiative aimed at designing treatments that direct a patient’s own immune cells to eliminate the earliest cellular drivers of age-related disease. The program applies generative AI and programmable RNA medicine to design single-administration, self-limiting in vivo cell therapies.
In plain terms, the goal is a one-and-done treatment that clears the first culprit cells behind aging-related conditions before they cause damage. It expands Insilico’s dual-purpose, aging-oriented discovery strategy from small molecules into RNA-encoded, in vivo cell engineering.
What the vaccines actually target
According to the company, many aging-related diseases are initiated and sustained by discrete cell populations with well-studied surface markers. Insilico cites three examples: senescent cells that secrete pro-inflammatory proteins (the senescence-associated secretory phenotype, or SASP), activated fibroblasts that drive fibrosis, and autoreactive lymphocytes that erode self-tolerance. Rather than treating downstream pathology, Longevity Vaccines are designed to eliminate these initiating cell populations within a preventive window and on a transient basis.
The approach builds on a growing body of peer-reviewed research showing that engineered T-cells can clear such cells and deliver durable functional benefits from a single therapeutic course. Insilico says selecting antigens for preventive medicine demands an exceptionally high bar.
Targets must appear at the earliest stages of pathogenesis while offering a wide therapeutic window. The company addresses this with its end-to-end Pharma.AI platform, which spans multi-omics target discovery (PandaOmics), generative biologics for de novo binder design, generative chemistry (Chemistry42) for ionizable lipids and delivery systems, and AI-assisted clinical trial design (inClinico). The platform ranks candidate surface antigens by evidence strength, expression timing, tissue specificity against a whole-body surface atlas, deliverability, and optimal construct design.
Candidates are then validated in automated laboratories, where experimental readouts continuously feed back to refine target rankings and optimize molecular designs. Insilico’s aging foundation models and Virtual Aging Cell supply the temporal, age-conditioned context required to pinpoint the earliest divergent cell states in a disease trajectory.
Starting with the immune system
The initiative will first focus on rejuvenation of the aging immune system, targeting the accumulation of senescent lymphocytes that drive immunosenescence, reduced vaccine responsiveness, and the rising susceptibility to infection and cancer with age. Additional indications under evaluation share defined initiating cell populations reachable by the same chassis, such as metabolic dysfunction and membranous nephropathy. “We built Insilico to treat aging and disease together, and to prove that AI can design medicines that deliver real patient impact,” said Alex Zhavoronkov, PhD, Founder and co-CEO of Insilico Medicine.
“Longevity Vaccines initiative extends that same rigor to preventive medicine—delivering programmable, single-dose therapies that clear the root-cause cells of age-related disease, starting with the immune system itself.”
The track record behind the bet
The initiative rests on Insilico’s experience with Rentosertib (ISM001-055), a first-in-class TNIK inhibitor whose target was nominated by AI for its role across multiple hallmarks of aging and whose molecule was fully AI-designed. It advanced from target identification to preclinical candidate in just 18 months, recently demonstrated lung capacity restoration in a randomized Phase IIa trial for idiopathic pulmonary fibrosis (IPF), and has entered Phase III development. Based on that experience, Insilico established its dual-purpose strategy of discovering therapeutics that tackle both specific clinical indications and fundamental biological aging processes.
Longevity Vaccines carries this strategy into a preventive, cell-clearing modality. Insilico recently reported total revenue of approximately $106 million in the first half of 2026, a 287% year-over-year increase, and achieved its first profitable half-year since listing, with an adjusted net profit exceeding $51 million.
That milestone was driven by out-licensing, co-development, and R&D collaborations with global partners including Eli Lilly, Servier, Takeda, SK Biopharmaceuticals, Qilu Pharmaceutical, Hygtia Therapeutics, CMS, and Tenacia. As of the latest practicable date, the total contract value of transactions announced by Insilico in 2026 reached approximately $7.3 billion, pushing the cumulative contract value of its major collaborations since 2021 to approximately $11 billion.
On the AI-driven R&D front, Insilico nominated nine development candidates within eight months of 2026 as of late August, setting a new company record for annual pipeline productivity and achieving eight clinical milestones across its proprietary and co-developed programs. The company also launched a comprehensive set of benchmarks that allow foundation models to be evaluated in all tasks.
What to watch next: whether Insilico names its first antigen targets for the immune-rejuvenation program, and how quickly the cmRNA-LNP chassis moves from automated-lab validation toward the clinic.
